Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.
The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.
The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.
UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.
Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.
S&P 500 companies' second-quarter earnings growth reached 70%, driven by the information technology
A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every
CAMBRIDGE, Mass., July 27, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chi
View interactive chart, options flow, and AI analysis for ABBV on Zorveq Finance.
Open ABBV Chart & Analysis →